

Surgery Name

Chronic Kidney Disease Review

Review Status: Review Required (eGFR date unavailable)
Current EMIS Status: Chronic Kidney disease stage 3

Results Overview

Patient Information

- **NHS Number:** 815861
- **Age:** 77 | **Gender:** Female

CKD Overview

- **Stage:** Stage 4 | **ACR criteria:** A1
- **Albumin-Creatinine Ratio (ACR):** 0.01 mg/mmol
- **Creatinine:**
 - **Current:** 173 $\mu\text{mol/L}$ | **Date:** nan
 - **3 Months Prior:** 0 $\mu\text{mol/L}$ | **Date:** nan
- **eGFR:**
 - **Current:** 25 ml/min/1.73m² | **Date:** nan
 - **3 Months Prior:** 0 ml/min/1.73m² | **Date:** nan
- **Anaemia Overview:**
 - **Haemoglobin:** 78 g/L | **Date:** 2023-10-04
 - **Current Status:** Severe Anaemia
- **Anaemia Management:** Consider ESA/Iron

Electrolyte and Mineral Bone Disorder (MBD) Management

- **Potassium:** 2.7 mmol/L | **Status:** Hypokalemia | **Date:** 2023-10-04
- **Phosphate:** 0.9 mmol/L | **Status:** Normal | **Date:** 2023-10-04
- **Calcium:** 1.35 mmol/L | **Status:** Hypocalcemia | **Date:** 2023-10-04
 - **MBD Status:** Check CKD-MBD
- **Vitamin D Level:** 17 ng/mL | **Date:** 2023-10-04
- **Vitamin D Status:** Vitamin D Deficiency

Blood Pressure

- **Classification:** Normal | **Date:** nan
- **Systolic / Diastolic:** 110 / 70 mmHg
- **Target BP:** <130/80 | **BP Status:** On Target

Kidney Failure Risk

- **2-Year Risk:** 0.09%
- **5-Year Risk:** 0.34%

The patient's 2- and 5-year kidney failure risk scores estimate the likelihood that their kidney disease will progress to kidney failure within the next 2 or 5 years. These scores are calculated based on the patient's current kidney function and other risk factors such as age, blood pressure, and existing health conditions. Understanding these risk scores helps in predicting disease progression and planning appropriate treatment strategies.

Care & Referrals

- **Multidisciplinary Care:** Not Indicated
- **Modality Education:** Not Indicated
- **Nephrology Referral:** Not Indicated
- **Persistent Proteinuria:** No Referral Needed

Medication Review

- **Current Medication:** Furosemide 40mg, Lisinopril 10mg, Atorvastatin 40mg
- **Review Medications:** Lisinopril
- **Contraindicated Medications:** No contraindications
- **Suggested Medications:** Erythropoiesis-stimulating agents for anaemia (e.g., Epoetin alfa, Darbepoetin alfa) (if indicated)
- **Statin Recommendation:** On Statin

Diabetes and HbA1c Management

- **HbA1c Level:** 27 mmol/mol | **Date:** 2023-10-04
- **HbA1c Management:** On Target

Lifestyle and Preventative Advice

- **Lifestyle Recommendations:** Refer to a renal dietitian for specialist dietary guidance, focusing on protein and potassium intake. Advise on sodium restriction and safe physical activity within the patient's tolerance. Discuss advance care planning and monitor for anemia, acidosis, and hyperphosphatemia.

NICE Guideline Recommendations

CKD Stage G4 Recommendations:

- **Specialist Management and Referral:** Routine referral to nephrology for co-management and preparation for potential renal replacement therapy. Regularly monitor eGFR, ACR, potassium, calcium, phosphate, and haemoglobin levels. Perform renal ultrasound if structural abnormalities or obstruction are suspected.
- **Management of Complications:** Monitor and manage anaemia, electrolyte imbalances, acidosis, and bone mineral disorders. Adjust medications that are renally excreted. Maintain BP targets as per guidelines.
- **Lifestyle and Preventive Measures:** Continue statin therapy (Atorvastatin 20 mg) for cardiovascular risk reduction. Provide vaccinations including influenza, pneumococcal, and COVID-19 as indicated. Regularly review medications to avoid nephrotoxic drugs and adjust dosages. Discontinue metformin if eGFR is less than 30 mL/min/1.73 m².
- **Patient Education:** Discuss potential need for renal replacement therapy and available options. Provide guidance on diet, fluid intake, and symptom management.

Surgery Name,
Add 1,
Add 2,
Belfast,
BT123456

Telephone: 028 90*****